SNDX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
83.3M
+14.4%
72.8M
+12.2%
64.9M
-5.6%
68.7M
+49.8%
45.9M
Cost of Revenue
14.0M
+336.3%
3.2M
+21.8%
2.6M
-2.7%
2.7M
+28.9%
2.1M
Gross Profit
69.3M
-0.4%
69.6M
+11.8%
62.2M
-5.7%
66.0M
+50.8%
43.8M
Operating Expenses
111.2M
+1.5%
109.6M
+1.2%
108.3M
+3.7%
104.4M
+3.1%
101.2M
R&D
67.5M
-0.8%
68.0M
+15.6%
58.8M
-25.2%
78.6M
+39.7%
56.3M
SG&A
43.7M
+5.2%
41.5M
+10.5%
37.6M
-24.7%
49.9M
+11.2%
44.9M
Operating Income
-41895000
-4.8%
-39995000
+13.1%
-46048000
-20.0%
-38362000
+33.2%
-57426000
EBITDA
-41889000
-4.7%
-39990000
+13.1%
-46044000
-20.0%
-38359000
+33.2%
-57423000
Net Income
-49433000
-0.1%
-49363000
-15.7%
-42673000
+37.3%
-68014000
-12.0%
-60715000
EPS (Basic)
$-0.55
+0.0%
$-0.55
-14.6%
$-0.48
+38.5%
$-0.78
-11.4%
$-0.70
EPS (Diluted)
$-0.55
+0.0%
$-0.55
-14.6%
$-0.48
+38.5%
$-0.78
-11.4%
$-0.70
Shares (Diluted)
89.8M
+0.9%
89.0M
+0.8%
88.3M
+1.0%
87.4M
+0.9%
86.6M
Syndax Pharmaceuticals (SNDX) — Financials